ReviewJournal of structural and functional genomics2007
Structural genomics as an approach towards understanding the biology of tuberculosis.
Review in Journal of structural and functional genomics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 23 citations in OpenAlex.
- Crystal structure of tRNA m(1)A58 methyltransferase TrmI from Aquifex aeolicus in complex with S-adenosyl-L-methionine.Journal of structural and functional genomics · 2014Article
- The progress made in determining the Mycobacterium tuberculosis structural proteome.Proteomics · 2011Review
- Molecular modeling studies of Fatty acyl-CoA synthetase (FadD13) from Mycobacterium tuberculosis--a potential target for the development of antitubercular drugs.Journal of molecular modeling · 2011Article
- Benefits of structural genomics for drug discovery research.Infectious disorders drug targets · 2009Review
- Structural genomics and drug discovery for infectious diseases.Infectious disorders drug targets · 2009Review
- Lessons from structural genomics.Annual review of biophysics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is a devastating disease of worldwide importance. The availability of the genome sequence of Mycobacterium tuberculosis (Mtb), the causative agent, has stimulated a large variety of genome-scale initiatives. These include international structural genomics efforts which have the dual aim of characterising potential new drug targets and addressing key aspects of the biology of Mtb. This review highlights the various ways in which structural analysis has illuminated the biological activities of Mtb gene products, which were previously of unknown or uncertain function. Key information comes from the protein fold, from bound ligands, solvent molecules, ions etc. or from unexpectedly modified amino acid residues. Most importantly, the three dimensional structure of a protein permits the integration of data from many sources, both bioinformatic and experimental, to develop testable functional hypotheses. This has led to many new insights into TB biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.